Theseus Pharmaceuticals, Inc.
SEC CIK 1745020 · THRX · last insider filing 2024-02-14
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Orbimed Advisors LLC | Director | filed 2021 - 2024 |
| Hayden Donald J JR | Director | filed 2022 - 2024 |
| Gordon Carl L | Director | filed 2021 - 2024 |
| Stein Steven H | Director | filed 2022 - 2024 |
| Dukes Iain D. | Director · Chairman | filed 2021 - 2024 |
| Yi Kathy | Director | filed 2021 - 2024 |
| Orbimed Capital GP VII LLC | Director | filed 2021 - 2024 |
| Orbimed Genesis GP LLC | Director | filed 2021 - 2024 |
| Clackson Timothy P | Director · President and CEO | filed 2021 - 2023 |
| Rome Michael E | Director | filed 2021 - 2021 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Dahms Bradford D. | President and CFO | filed 2021 - 2024 |
| Shakespeare William | See Remarks | filed 2021 - 2023 |
| Kerstein David | Chief Medical Officer | filed 2021 - 2023 |
| Rivera Victor | Chief Scientific Officer | filed 2021 - 2023 |
| Dalgarno David | Chief Technical Officer | filed 2021 - 2022 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.